All Updates

All Updates

icon
Filter
Partnerships
BenevolentAI and AstraZeneca extends collaboration with novel target for systemic lupus erythematosus
AI Drug Discovery
Jun 25, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
AI Drug Discovery

AI Drug Discovery

Jun 25, 2024

BenevolentAI and AstraZeneca extends collaboration with novel target for systemic lupus erythematosus

Partnerships

  • AI-powered biotechnology company BenevolentAI, in collaboration with AstraZeneca, has announced that a novel target for systemic lupus erythematosus (SLE) has been added to its discovery portfolio.

  • The partnership, initiated in 2019, leverages BenevolentAI's AI drug discovery platform to develop novel therapeutic targets tested and validated by AstraZeneca. The collaborative research was initiated focusing on idiopathic pulmonary fibrosis and chronic kidney disease and was extended in 2022 , expanding the study to include heart failure and SLE.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.